What's next?

What's next is: the days of showing up with samples, lunch and a canned message are gone. No one cares about you and your doll. BI is slow to learn this. Future pharma brings much more value or they won't survive the landscape of health care. As reps, we need to evolve our skills and abilities.

 

Preach

 

For those that are NOT afraid, maybe you should be. Has anyone seen that a new study was just reported about...that Farxiga has shown to reduce HF in patients WITHOUT diabetes! They have a better a better a1c reduction and it sounds like it will be a better CV indication so where does that leave Jardiance?

https://www.bloomberg.com/news/articles/2019-08-20/astrazeneca-s-farxiga-lowers-death-risk-in-heart-failure-study

 

Go back and research our data

 

They will all be seen as the same. It will come down to price and formulary contracts. BI has never done a great job with that.

 

Really...look at our coverage. Look over the PI's. If thats your conclusion, I have no words for you.

 

At the top of the market share and sales!! Farxiga will never beat Jardiance again and the HF data for Jardiance will smother this data